Study S000193

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06131372
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 626
Start: 2024-04-01
Primary completion: 2025-09-24
Lead sponsor: Novo Nordisk A/S
Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1291-5907; EUDRACT_NUMBER:2023-505857-42; NIH:2023

Registered primary outcomes

Change in urinary albumin-to-creatinine ratio (UACR) [From baseline (week 0) to end of treatment (week 26)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.